When to Start HPV Testing for Cervical Cancer Screening
Begin routine cervical cancer screening at age 25 years with primary HPV testing every 5 years as the preferred strategy. 1
Screening Initiation and Strategy
Age to Begin Screening
- Start screening at age 25 years for all individuals with a cervix at average risk 1
- This represents a change from previous recommendations that initiated screening at age 21 years 1
- Do not screen individuals younger than 21 years, regardless of sexual activity history, as HPV infections in adolescents are typically transient and cervical cancer is extremely rare in this age group 1, 2
Preferred Testing Method
Primary HPV testing alone every 5 years is the preferred screening strategy for individuals aged 25-65 years 1. This recommendation is based on:
- Superior sensitivity for detecting high-grade precancerous lesions compared to cytology alone 2, 3
- Greater long-term reassurance when negative 3
- Better detection of glandular lesions and adenocarcinoma precursors 1
Alternative Acceptable Strategies (When Primary HPV Testing Unavailable)
If FDA-approved primary HPV testing is not accessible 1:
- Cotesting (HPV testing combined with cytology) every 5 years, OR
- Cytology alone every 3 years
These alternatives should be phased out once primary HPV testing becomes widely available without barriers 1
Special Considerations: No Earlier Testing for Most Risk Factors
Standard Risk Factors Do NOT Warrant Earlier Screening
The following do not change the age 25 initiation recommendation 1:
- HPV vaccination status - vaccinated individuals follow the same screening schedule 1
- Multiple sexual partners or early sexual activity initiation 4
- Lesbian, gay, bisexual, transgender, and queer individuals follow standard guidelines 4
High-Risk Populations Requiring Modified Approach
Earlier or more frequent screening may be warranted for 5, 4:
- Individuals with immunosuppression (HIV infection, organ transplant recipients, chronic corticosteroid use)
- History of in utero diethylstilbestrol (DES) exposure
- Previous history of cervical intraepithelial neoplasia grade 2 or higher within the past 25 years
For these high-risk groups, clinician-collected specimens remain preferred over self-collection 5
Screening Cessation
Discontinue screening at age 65 years if adequate prior screening has been documented 1:
- Two consecutive negative primary HPV tests at ages 60 and 65 years (preferred), OR
- Two negative cotests, OR
- Three consecutive negative cytology tests within the past 10 years, with the most recent test within 3-5 years 1, 5
Continue screening beyond age 65 if 1:
- History of cervical intraepithelial neoplasia grade 2 or more severe disease within the past 25 years
- Inadequate documentation of prior negative screening
- Current immunosuppression 5
Key Implementation Points
Self-Collection Option
Self-collected vaginal specimens for HPV testing are now acceptable for average-risk individuals aged 25-65 years when using FDA-approved collection devices and assays 5. However:
- Clinician-collected cervical specimens remain preferred 5
- Self-collection requires 3-year screening intervals (not 5 years) due to slightly lower sensitivity 5
- Most HPV-positive individuals will still require clinician follow-up 5
Common Pitfalls to Avoid
- Do not screen before age 25 - this leads to unnecessary procedures for transient infections that would resolve spontaneously 1
- Do not screen after hysterectomy with cervix removal for benign indications and no history of high-grade lesions 1, 2
- Do not alter screening based on vaccination status - vaccinated individuals require the same screening schedule 1
- Do not use shorter intervals than recommended - this increases harms without proportional benefit 1